Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance
View original at globenewswire.com“der sonstige Umsatz stieg auf CHF 38.0 Mio. (GJ 2024: CHF 13.7 Mio.), einschliesslich CHF 30.9 Mio. Umsatz aus Verträgen mit BARDA[1] (GJ 2024: CHF 10.2 Mio.) und CHF 4.3 Mio. Umsatz aus der Vereinbarung mit CARB-X[2] (GJ 2024: CHF 1.8 Mio.).”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Cumulative positive cash flows of approximately CHF 600 million are expected from Cresemba and Zevtera over the next five-year period
80% confidenceCresemba generic competition could impact US market from Q4 2027 and European market from H2 2028
80% confidenceZevtera is expected to gain increasing momentum in the USA from Q2 2026
80% confidencePotential additional non-dilutive R&D funding of approximately USD 330 million from existing BARDA contracts may be allocated in further tranches
80% confidenceRoyalty revenues expected to rise to approximately CHF 120 million and milestone payments to CHF ~35 million in FY2026
80% confidenceFY2026 total revenue is expected to increase by approximately 10%, R&D expenses by approximately 20%, and operating profit by approximately 20%
80% confidenceBasilea reduced the nominal value of outstanding convertible bonds by approximately 22% to CHF 76 million and increased cash position to CHF 162 million in 2025
80% confidencePhase-3 studies for Fosmanogepix are on track for a data readout in early 2028
80% confidenceBasilea aims to have four drugs on the market by 2030 as well as a broadly positioned R&D pipeline
80% confidenceSince early 2022, Basilea has reduced its financial debt by approximately CHF 145 million
80% confidenceFosmanogepix and Ceftibuten-Ledaborbactam have potential to double today's in-market revenues by 2030
80% confidenceBasilea has developed into a profitable company with continuously double-digit growth in in-market revenues of products and a leading R&D pipeline in its focus area
80% confidenceCresemba and Zevtera-based revenues expected to reach approximately CHF 200 million in FY2026
80% confidence
Cited in these Via News reports
- AI Recruitment Platform Hudson Hits $48M Revenue Post-Merger as Asia Pacific Dominance Fuels Global Expansion →
- AI Startups Pull $716M as Global VC Shifts from Crypto to Enterprise Automation →
- Blackstone and KKR Lead Global Shift to Permanent Capital as Private Equity Reinvents Itself →
- European venture funds lock €150M into deeptech and defense as capital splits into sector specialists →
- Private Equity Targets Packaging Assets Across Markets as Earnings Season Reveals 20% Swings in Tech Valuations →
- Tech Stocks Jump 8-12% as US Policy Clarity Reverses Global Selloff While Crypto Crashes 22% →